Seaport Therapeutics, Inc. - 8-K Filing

Seaport Therapeutics reported Q2 2026 financial results with $427.3M in cash as of June 30, 2026. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $SPTX

Read the full article at SEC EDGAR

More Regulatory news